Remikiren

Remikiren
Clinical data
ATC code	C09XA01 (WHO) ;
Pharmacokinetic data
Protein binding	83%
Identifiers
	IUPAC name (2R)-2-(tert-butylsulfonylmethyl)-N-[(2S)-1-; {[(2R,3S,4R)-1-cyclohexyl-4-cyclopropyl-3,4-; dihydroxybutan-2-yl]amino}-3-(3H-imidazol-; 4-yl)-1-oxopropan-2-yl]-3-phenylpropanamide;
CAS Number	126222-34-2;
PubChem CID	5462340;
DrugBank	APRD00163;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C33H50N4O6S
Molar mass	630.839 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Sheng Shi, M.D. [2]

Overview

Remikiren is a renin inhibitor under development for the treatment of hypertension (high blood pressure). It was first developed by Hoffmann–La Roche in 1996.^[1]

↑ Richter WF, Whitby BR, Chou RC (1996). "Distribution of remikiren, a potent orally active inhibitor of human renin, in laboratory animals". Xenobiotica. 26 (3): 243–54. doi:10.3109/00498259609046705. PMID 8730917.

Clinical data

ATC code	C09XA01 (WHO)
Pharmacokinetic data
Protein binding	83%
Identifiers
IUPAC name (2R)-2-(tert-butylsulfonylmethyl)-N-[(2S)-1- {[(2R,3S,4R)-1-cyclohexyl-4-cyclopropyl-3,4- dihydroxybutan-2-yl]amino}-3-(3H-imidazol- 4-yl)-1-oxopropan-2-yl]-3-phenylpropanamide
CAS Number	126222-34-2
PubChem CID	5462340
DrugBank	APRD00163
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₃₃H₅₀N₄O₆S
Molar mass	630.839 g/mol